BNTX

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

BioNTech appoints new CEO; advances 14-pivot pipeline while guiding 2026

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>BioNTech reported Q2 2026 revenue of €105.6m and trimmed 2026 revenue guidance to €1.6–1.9B, while maintaining €16.6B in cash. Guido Oelkers will assume the CEO role by February 1, 2027, as the company advances a 14-pivot oncology pipeline and anticipates multiple late-stage readouts in 2026; the €613m Bristol Myers Squibb collaboration revenue is expected in Q3, supporting near-term liquidity and optionality on R&amp;D investments.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Guido Oelkers named BioNTech CEO; to take office by Feb 1, 2027.</li><li>Pipeline expanded to 14 pivotal trials and 10+ novel combinations.</li><li>Pumitamig shows first-line NSCLC efficacy; ASCO 2026 data highlighted.</li><li>Revised 2026 guidance: €1.6–1.9B revenue; €16.6B cash; €613m BMS revenue in Q3.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>BioNTech SE (BNTX)</strong>: Core subject; CEO transition and pipeline milestones drive near-term volatility and long-term value.</li><li><strong>Bristol Myers Squibb (BMY)</strong>: ROSETTA program contributes potential milestone/collaboration revenue; €613m expected in Q3 2026.</li><li><strong>Pfizer (PFE)</strong>: Partner on XFG variant-adapted COVID-19 vaccine; regulatory activity supports near-term revenue potential.</li><li><strong>CureVac (CVAC)</strong>: CureVac acquired in 2025; integration adds to R&amp;D spend and pipeline breadth.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. Fits as BioNTech’s interim results, leadership transition, and strategic pivots (pipeline milestones, partnerships, and guidance) dictate near-term sentiment and valuation.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Q3 2026: €613m BMS collaboration revenue expected, bolstering near-term top line.</li><li>Guidance cut reflects COVID vaccine demand softness; timing shifts to H2.</li><li>CEO transition introduces execution risk; potential for volatility around leadership change.</li><li>Strong balance sheet and ongoing share buyback provide flexibility for pipeline investments.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Second quarter 2026 revenues €105.6 million; year-to-date €223.7 million.</li><li>Cash, cash equivalents and securities: €16,634.2 million as of 6/30/2026.</li><li>R&amp;D: IFRS €551.0 million (Q2); adjusted €477.1 million; year-to-date adjusted €1,004.2 million.</li><li>SG&amp;A: €197.8 million (Q2); year-to-date €348.6 million.</li><li>Revised 2026 guidance: Revenue €1.6–€1.9 billion; adjusted R&amp;D €2.0–€2.3 billion; adjusted SG&amp;A €0.7–€0.8 billion.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish over the next 3–6 months on Q3 revenue and key readouts, but watch CEO transition risk.</p>
  </section>
</section>


<article><h2>BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update</h2>

<section>
  <p><strong>Mainz, Germany</strong>, August 4, 2026 (GLOBE NEWSWIRE) — BioNTech SE (<strong>NASDAQ: BNTX</strong>, "BioNTech" or "the Company") today reported financial results for the three and six months ended June 30, 2026 and provided an update on its corporate progress.</p>
  <p>In the first half of 2026, the Company advanced its oncology pipeline, initiated six pivotal trials, and demonstrated momentum for its novel-novel combination therapy strategy at medical congresses. The Company also highlighted leadership development, noting Guido Oelkers will assume BioNTech's CEO role by February 1, 2027, at the latest. A conference call and webcast are scheduled for August 4, 2026, at 8:00 a.m. EDT (2:00 p.m. CEST).</p>
</section>

<section>
  <h3>Leadership Update: CEO Appointment and Board Alignment</h3>
  <ul>
    <li><strong>Guido Oelkers, Ph.D., appointed to BioNTech Management Board as Chief Executive Officer</strong>, taking office by February 1, 2027, at the latest</li>
  </ul>
</section>

<section>
  <h3>Pipeline Progress and Strategic Milestones</h3>
  <ul>
    <li><strong>Advanced diversified pipeline now with 14 ongoing pivotal clinical trials</strong> and more than ten novel-novel combinations across major tumor types</li>
    <li><strong>Multiple milestones achieved in 2026</strong>, including initiation of six pivotal trials - five for pumitamig and one for B7-H3-targeting ADC candidate elfetabart drozuntecan; upcoming 2026 catalysts include three late-stage readouts expected across immunomodulators, antibody-drug conjugate and mRNA cancer immunotherapies</li>
  </ul>
</section>

<section>
  <h3>Clinical Milestones: Pumitamig and Related Therapies</h3>
  <ul>
    <li><strong>Pumitamig in combination with chemotherapy showed encouraging efficacy in first line non-small cell lung cancer</strong> and results presented at 2026 ASCO Annual Meeting became the third global pumitamig data set consistently showing efficacy across PD-L1 expression levels</li>
  </ul>
</section>

<section>
  <h3>Regulatory Update: COVID-19 Vaccine Variant-Adapted Booster</h3>
  <ul>
    <li><strong>Approval received for new variant-adapted COVID-19 vaccine by the European Commission</strong>; further launch preparation underway as recommended by regulators</li>
  </ul>
</section>

<section>
  <h3>Financial Highlights: Second Quarter 2026</h3>
  <ul>
    <li><strong>Second quarter 2026 revenues of €105.6 million</strong>, adjusted <em>R&D expenses</em> of €477.1 million (IFRS <em>R&D expenses</em> of €551.0 million), and adjusted <em>SG&A expenses</em> of €197.8 million</li>
  </ul>
</section>

<section>
  <h3>Guidance and Outlook for 2026</h3>
  <ul>
    <li><strong>Revising full year 2026 financial guidance range for revenues to €1.6–1.9 billion</strong>, adjusted <em>R&D expenses</em> to €2.0–2.3 billion, and maintaining adjusted <em>SG&A expenses</em> of €700–800 million</li>
  </ul>
</section>

<section>
  <h3>Liquidity and Financial Position</h3>
  <ul>
    <li><strong>Maintained strong financial position</strong> with cash, cash equivalents and security investments of <strong>€16.6 billion</strong></li>
  </ul>
</section>

<section>
  <p><strong>Conference call and webcast scheduled for August 4, 2026, at 8:00 a.m. EDT (2:00 p.m. CEST)</strong></p>
</section>

<section>
  <p><strong>MAINZ, Germany</strong> — BioNTech SE (<strong>NASDAQ: BNTX</strong>, "BioNTech" or "the Company") today reported financial results for the three and six months ended June 30, 2026 and provided an update on its corporate progress.</p>
</section>

<section>
  <p>"In the first half of 2026, we made important progress in turning our mission into reality. We significantly advanced our late-stage oncology pipeline, with six pivotal trials initiated; we pioneered the generation of first-in-class global Phase 2 data for an investigational PD-L1xVEGF bispecific antibody in first-line non-small cell lung cancer across PD-L1 expression levels and histologies; and we demonstrated at medical congresses that our novel-novel combination therapy strategy is gaining momentum," said <strong>Prof. Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech</strong>. "We look forward to welcoming BioNTech's next CEO. Guido Oelkers will take office by February 1, 2027, at the latest, and, together with the Management Board and teams across the company, is expected to continue to write the BioNTech success story."</p>
</section></article>

BioNTech reported Q2 2026 revenue of €105.6m and trimmed 2026 revenue guidance to €1.6–1.9B, while maintaining €16.6B in cash. Guido Oelkers will assume the CEO role by February 1, 2027, as the company advances a 14-pivot oncology pipeline and anticipates multiple late-stage readouts in 2026; the €613m Bristol Myers Squibb collaboration revenue is expected in Q3, supporting near-term liquidity and optionality on R&D investments.

News insight

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

AI summary

Sentiment rationale

Key facts

Corporate Developments